Acetic Acid → HCID 70896181, compound
Reaction equation
C(O[CH2:5][C:6]1[CH:14]=[CH:13][C:12]2[CH2:15][NH:16][C@@H:17]([CH:20]3[CH:25]4[CH2:26][CH2:27][N:22]([CH2:23][CH2:24]4)[CH2:21]3)[C:18](=[O:19])[N:10]3[C:11]=2[C:7]=1[CH:8]=[CH:9]3)(=O)C.C(O)(=O)C>CO.[Pd]>[CH3:5][C:6]1[CH:14]=[CH:13][C:12]2[CH2:15][NH:16][C@@H:17]([CH:20]3[CH:25]4[CH2:24][CH2:23][N:22]([CH2:27][CH2:26]4)[CH2:21]3)[C:18](=[O:19])[N:10]3[C:11]=2[C:7]=1[CH:8]=[CH:9]3Participants
Reactant 2
Product 1
Reagents, catalysts & solvents 2
Procedure
(S)-(1-Oxo-2-(quinuclidin-3-yl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)methyl acetate (124 mg, 0.34 mmol) from Step C above was dissolved in methanol (7 ml) and glacial acetic acid (3 ml). Excess 10% palladium on carbon was added and the suspension was stirred under an atmosphere of hydrogen (balloon pressure) overnight. The suspension was filtered through Celite and the filtrate was concentrated under reduced pressure and purified by column chromatography (silica gel, 90:10:1 methylene chloride/methanol/concentrated ammonium hydroxide) and preparative TLC (90:10:10 methylene chloride/methanol/concentrated ammonium hydroxide) to afford (S)-7-methyl-2-(quinuclidin-3-yl)-3,4-dihydro-[1,4]diazepino[6,7,1-hi]indol-1(2H)-one. This material was dissolved in methanol and treated with HCl (1.25 M solution in methanol) and the mixture was concentrated under reduced pressure. The residue was lyophilized from water to afford (S)-7-methyl-2-(quinuclidin-3-yl)-3,4-dihydro-[1,4]diazepino[6,7,1-hi]indol-1(2H)-one hydrochloride (100 mg, 85%) as a white solid: 1H NMR (500 MHz, CD3OD) δ 7.80 (d, J=4.0 Hz, 1H), 7.75 (d, J=3.8 Hz, 1H), 7.17 (t, J=8.0 Hz, 1H), 7.17 (t, J=8.0 Hz, 1H), 4.90 (s, 1H), 4.22 (br s, 1H), 4.11 (br s, 1H), 3.77-3.72 (m, 2H), 3.48-3.29 (m, 6H), 2.35 (d, J=8.0 Hz, 1H), 2.21 (s, 3H), 2.06-1.96 (m, 4H); MS (ESI+) m/z 310 (M+H).
Workup
- filtrationThe suspension was filtered through Celite
- concentrationthe filtrate was concentrated under reduced pressure
- custompurified by column chromatography (silica gel, 90:10:1 methylene chloride/methanol/concentrated ammonium hydroxide) and preparative TLC (90:10:10 methylene chloride/methanol/concentrated ammonium hydroxide)
Sources & evidence
- ORD record
- ord-9914a7b971a74792b35b96e7c4682152
- Source dataset
- uspto-grants-2014_04
- Patent number
- US08710046B2
Reaction notes
Loading…